Ultragenyx Pharmaceutical Inc (RARE) Directors and Executive Officers

Corsee D. Sanders
Director

Theodore A. Huizenga
Senior Vice President and Chief Accounting Officer (Principal Accounting Officer)

Michael Narachi
Director

Matthew K. Fust
Director

Daniel G. Welch
Chairman of the Board

Emil D. Kakkis, M.D., Ph.D.
President and Chief Executive Officer (Principal Executive Officer)
Director

Amrit Ray
Director

Shehnaaz Suliman
Director

Howard Horn
Executive Vice President, Chief Financial Officer, Corporate Strategy (Principal Financial Officer)

Deborah Dunsire, M.D.
Director ,

Ultragenyx Pharmaceutical Inc currently has 1371 employees.

News about Ultragenyx Pharmaceutical Inc Key Personnel

Ultragenyx Pharmaceutical Fuels Strategic Growth and Talent Acquisition through Targeted Stock Grants amid Competitive Landscape,

Ultragenyx Pharmaceutical Inc. Strengthens Workforce and Growth Potential Through Strategic Stock Grant InitiativesOn March 19, 2025, Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company specializing in therapies for rare and ultrarare diseases, announced the granting of 21,806 restricted stock units (RSUs) to 16 newly hired non-executive officers. This initiative, approved by the company s compensation committee, falls under the Ultragenyx Employment Inducement Plan and aligns with Nasdaq Listing Rule 5635(c)(4). The RSUs were granted with a grant date of March 16, 2025, as part of a proactive strategy to attract and retain top talent essential for the company’s ongoing innovation a...

Ultragenyx Lights the Way for Pediatric HoFH Treatment: Groundbreaking Approval of Evkeeza Amidst Financial and Strategic Trials,

Ultragenyx Pharmaceutical s Groundbreaking Development in Pediatric HoFH Treatment Amidst Operational Challenges IntroductionIn a significant advancement for pediatric healthcare, the European Commission (EC) has extended the approval of Evkeeza (evinacumab) to children as young as six months diagnosed with Homozygous Familial Hypercholesterolemia (HoFH). This ultrarare genetic disorder is characterized by extremely high cholesterol levels, leading to severe cardiovascular complications. The approval positions Evkeeza as the first and only medication authorized in the European Union for this age group, marking a crucial milestone in the treatment of HoFH. Key Developments- Approval of Evkeeza: The EC s app...

Ultragenyx Submits FDA Application for Groundbreaking Gene Therapy for Sanfilippo Syndrome Type A Amid Revenue Growth and Share Price Decline,

Ultragenyx Pharmaceutical Inc. a leader in the development of innovative gene therapies for rare genetic diseases, has made a significant move in the field of genetic therapeutics with the submission of a Biologics License Application to the U.S. FDA for its investigational gene therapy, UX111. This application is aimed at treating Sanfilippo Syndrome Type A (MPS IIIA), a rare and progressive neurodegenerative disorder that severely affects children s cognitive and physical development. If approved, UX111 would mark a milestone as the first approved therapy specifically for Sanfilippo Syndrome Type A in the U.S. marketplace—a critical development for patients and families affected by this debilitating cond...

Ultragenyx Achieves Breakthrough Therapy Status for Osteogenesis Imperfecta as OKX Explorer Enhances Web3 Analytics with Bitlayer Integration

In a significant stride for patients with rare bone disorders, Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a company committed to innovating treatments for rare and ultra-rare diseases, has proudly announced that it has been granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for its investigational drug, setrusumab (UX143). This therapy targets the reduction of fracture risk in patients suffering from osteogenesis imperfecta (OI) Types I, III, or IV, specifically in individuals aged two years and older. The FDA s designation underscores the potential of setrusumab to provide a meaningful therapeutic advancement for patients who face the daily challenges posed by this b...

Ultragenyx's Groundbreaking Milestones in Sanfilippo Syndrome Treatment Amidst Financial Revival

In a groundbreaking development, Ultragenyx Pharmaceutical Inc has recently announced its plans to file for accelerated approval of UX111 for the treatment of Sanfilippo Syndrome Type A (MPS IIIA). This announcement comes as the company reached an agreement with the FDA regarding the use of cerebral spinal fluid (CSF) heparan sulfate (HS) as a surrogate marker for accelerated approval. These milestones carry significant implications for the company s future and the patients affected by this devastating disease.
Expansion into Sanfilippo Syndrome Treatment:
Sanfilippo Syndrome, also known as MPS IIIA, is a rare and severe genetic disorder that primarily affects the brain and nervous system o...